| Sep-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Dec-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 6.28% | 6.31% | 6.31% | 6.31% | 6.31% |
Indian | 39.51% | 39.46% | 39.45% | 39.44% | 39.44% |
Total Promoter | - | - | - | - | - |
Institutions | 12.89% | 13.17% | 13.82% | 24.12% | 16.03% |
Non-Institutions | 41.31% | 41.04% | 40.4% | 30.11% | 38.2% |
Total Non-Promoter | 54.2% | 54.21% | 54.22% | 54.23% | 54.23% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
